Metformin/Dapagliflozin/Sitagliptin

二甲双胍/达格列净/西格列汀

Report date: 2025/07/30 14:53:39

Base Information

Drug NameMetformin/Dapagliflozin/Sitagliptin
Drug Alias NameGMRx4
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsSodium/glucose cotransporter 2 inhibitorsDipeptidyl peptidase IV inhibitors
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsYes Metformin HydrochlorideSitagliptin HydrochlorideDapagliflozin Propanediol Monohydrate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGeorge Medicines PTY LtdGeorge Medicines UK Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGeorge Medicines UK Ltd
Inactive CompaniesGeorge Medicines PTY Ltd
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A